title: Reply to 'Comment on: Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizmab'.
authors: Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
authors: T D
authors: TD
authors: Papakostas
authors: Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
authors: D
authors: D
authors: Vavvas
authors: Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
authors: D
authors: D
authors: Eliott
authors: Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
authors: L A
authors: LA
authors: Kim
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema; D012170:Retinal Vein Occlusion; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab